Claritin

Claritin is a consumer allergy-relief brand best known for loratadine, a second-generation antihistamine used to relieve symptoms associated with seasonal allergic rhinitis and other allergies. The brand was developed and commercialized by Schering-Plough, which initially marketed loratadine as a prescription medicine before the product became one of the most prominent nonprescription allergy treatments in the United States. Loratadine works primarily by blocking peripheral histamine H1 receptors. Compared with many older antihistamines, it was positioned around effective symptom relief with less tendency to cause drowsiness when used as directed. Claritin products are commonly marketed for symptoms such as sneezing, runny nose, itchy nose or throat, and itchy or watery eyes. Product availability, formulations, indications, and labeling vary by country. The U.S. brand moved from prescription to over-the-counter distribution in 2002 after the U.S. Food and Drug Administration approved nonprescription marketing of loratadine. This change expanded Claritin’s access through mass retailers, pharmacies, supermarkets, and other consumer channels. The brand subsequently became part of the large U.S. self-care allergy category, competing with products such as Zyrtec, Allegra, and store-brand loratadine. Claritin’s portfolio has included standard tablets, rapidly dissolving or orally disintegrating formats, chewable tablets, syrups or other liquid formulations, and combination products that pair loratadine with a decongestant. Combination products have been marketed under variants such as Claritin-D in the United States, although regulatory status and product composition differ by market. The core brand remains associated with once-daily loratadine-based allergy treatment rather than with a single universal product format. In 2014, Bayer agreed to acquire Merck’s consumer-care business, which included a portfolio of over-the-counter brands. Following completion of that transaction, Claritin became part of Bayer’s Consumer Health business. Bayer continues to market Claritin internationally, subject to local regulatory requirements and commercial arrangements. The brand’s present positioning emphasizes accessible, everyday allergy management and non-drowsy relief, while its commercial identity has been reinforced through broad retail distribution and seasonal advertising.

Claritin is the principal consumer brand associated with loratadine, a second-generation antihistamine developed for the treatment of allergic symptoms. The medicine was commercialized by Schering-Plough, a pharmaceutical company whose prescription and consumer-health operations included allergy products. Loratadine was initially supplied as a prescription medicine in the United States under the Claritin name. The product’s commercial distinction was its attempt to provide effective histamine-related symptom control with less sedation than many first-generation antihistamines. That attribute became central to Claritin’s brand identity and later advertising, although individual responses to antihistamines can vary and the product labeling does not imply that every user will experience identical effects. The core treatment is intended for symptoms associated with allergic rhinitis and related allergies, rather than for every cause of nasal or eye irritation. A major turning point came in 2002, when the U.S. Food and Drug Administration approved loratadine for over-the-counter use. The switch made Claritin available without a prescription and allowed it to compete directly for consumer purchases in pharmacies, supermarkets, mass merchants, and other retail settings. The transition also helped establish a broader U.S. market for branded, nonprescription allergy treatments. Other loratadine brands and private-label equivalents subsequently expanded consumer choice. After the OTC launch, Claritin developed a family of formulations and line extensions. These have included once-daily tablets, orally disintegrating forms, chewable products, pediatric products, liquids, and combination products containing a decongestant. Claritin-D products are designed for allergy symptoms accompanied by nasal congestion, but they contain additional active ingredients and are subject to different warnings, restrictions, and availability rules. Formulations and names are not identical across national markets. Claritin’s ownership changed as the pharmaceutical industry consolidated. Schering-Plough merged with Merck & Co. in 2009, placing the brand within the combined company’s consumer-care activities. In 2014, Bayer announced and completed the acquisition of Merck’s consumer-care business. Claritin consequently became part of Bayer Consumer Health, alongside other self-care brands. Bayer has continued to manage the brand’s international marketing, product development, and distribution within the regulatory frameworks of individual countries. The brand is now a mature international OTC allergy franchise. Its competitive environment includes branded antihistamines such as Zyrtec and Allegra, as well as generic and retailer-owned loratadine products. Claritin’s enduring proposition is built around convenient, generally once-daily allergy relief and the consumer-recognizable promise of non-drowsy positioning. Its current commercial scope is therefore broader than the original prescription product, but remains centered on loratadine-based treatment for allergy symptoms.

• 2014

  Bayer acquires Merck Consumer Care

  [2]Bayer to acquire Merck’s consumer-care businessbayer.com

  Bayer acquired Merck’s consumer-care business, transferring Claritin to Bayer Consumer Health.

• 2009

  Schering-Plough merges with Merck

  [3]Merck and Schering-Plough complete mergermerck.com

  The merger placed Schering-Plough’s brands, including Claritin, within the combined Merck organization.

• 2002

  U.S. over-the-counter switch

  [1]Claritin loratadine FDA labelingaccessdata.fda.gov

  FDA approval allowed loratadine products such as Claritin to be sold without a prescription in the United States.

• 1993

  Claritin enters the U.S. prescription market

  [1]Claritin loratadine FDA labelingaccessdata.fda.gov

  Loratadine was introduced in the United States as a prescription allergy medicine under the Claritin brand.

Everyday, non-drowsy allergy relief for seasonal and indoor allergy symptoms.

• Antihistamine tablets

  Claritin 24 Hour Allergy

  The core Claritin line uses loratadine to relieve common allergy symptoms, including sneezing, runny nose, itchy nose or throat, and itchy or watery eyes. The standard product is positioned as a once-daily treatment and is sold in several tablet formats depending on the market. Product labeling, dosage, and approved indications should be checked locally.

• Orally disintegrating antihistamine tablets

  Claritin RediTabs

  RediTabs are an orally disintegrating version of loratadine designed for consumers seeking a tablet that dissolves in the mouth without conventional swallowing. The format extends the core Claritin proposition into a convenience-oriented product. Availability and exact formulation vary by country and may change over time.

• Pediatric allergy medicine

  Children’s Claritin

  Children’s Claritin comprises pediatric loratadine products, including chewable tablets and liquid formulations in some markets. These products are intended for age groups and doses specified on the applicable label. They extend the brand to family allergy care while retaining the loratadine-based, non-drowsy positioning.

• Antihistamine and decongestant combination

  Claritin-D

  Claritin-D combines loratadine with pseudoephedrine to address allergy symptoms together with nasal congestion. Because pseudoephedrine has additional precautions and purchasing restrictions in some jurisdictions, Claritin-D is not interchangeable with standard Claritin. The available strengths, pack sizes, and regulatory conditions depend on the market.

• 2014

  Transfer of Claritin to Bayer Consumer HealthM&A

  Background

  Merck decided to divest its consumer-care business as part of a broader portfolio and corporate strategy.

  Action taken

  Bayer acquired Merck’s consumer-care business, including the Claritin brand portfolio.

  Aftermath

  Claritin became part of Bayer’s global consumer-health operations and continued as an OTC allergy brand.

  Source

• 2002

  Move from prescription to over-the-counter distributionStrategy

  Background

  Loratadine had been sold as a prescription allergy medicine, limiting access to physician-mediated channels. FDA review supported nonprescription marketing in the United States.

  Action taken

  The Claritin loratadine product was made available over the counter, allowing distribution through ordinary retail and pharmacy channels.

  Aftermath

  The switch broadened consumer access and established Claritin as a major branded product in the U.S. self-care allergy category.

  Source

• 2014

  Bayer agrees to acquire Merck Consumer Care[2]Bayer to acquire Merck’s consumer-care businessbayer.com

  M&A

  Bayer announced an agreement to acquire Merck’s consumer-care business, bringing brands including Claritin into Bayer’s consumer-health portfolio after the transaction closed.

• 2002

  FDA approves nonprescription use of Claritin loratadine[5]FDA批准氯雷他定（Claritin）转为非处方药fda.gov

  Regulation · Other

  The U.S. Food and Drug Administration approved loratadine for over-the-counter sale, moving Claritin from prescription-only distribution into the mass-market self-care channel.

1. 1Claritin loratadine FDA labelingaccessdata.fda.gov
2. 2Bayer to acquire Merck’s consumer-care businessbayer.com
3. 3Merck and Schering-Plough complete mergermerck.com
4. 4Claritin products and consumer informationclaritin.com
5. 5FDA批准氯雷他定（Claritin）转为非处方药fda.gov